Our strategic collaborations, including a Cooperative Research and Development Agreement with the National Cancer Institute, have enabled us to advance an industry-leading pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates to treat both hematological (blood-based) and solid cancers.
With an unrelenting focus on delivering a cure, our team is successfully executing on our strategy to bring life-saving therapies to patients. Our most advanced candidate, KTE-C19, is currently in a pivotal trial for the treatment of refractory, aggressive non-Hodgkin lymphoma (NHL), and we estimate interim data to be available in 2016. We plan to follow with additional indications for KTE-C19, while continuing to advance our pipeline of CAR and TCR product candidates.
We are changing the paradigm of cancer treatment.